AS2401 - From Concept to Counsel: Relating results to reality

Thursday, November 21, 2024

07:15 - 08:15 AT Time

Location: Ballroom B3

Presenter(s)

Tammy Cadieux, R.N, CDE, study coordinator

nurse
Centre de medecine metabolique de Lanaudiere
terrebonne, Quebec, Canada

Disclosure(s): Elli Lilly, novonordisk, Tandem, Medtronic, Sanofi, Abbott, Dexcom, BI, Novartis, Bayer, Inventiva: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing)
RG

Robert Goldberg, MD

Assistant Professor, Department of Medicine; Staff Endocrinologist
University of Toronto, Trillium Health Partners
University of Toronto
Toronto, Ontario, Canada

Disclosure(s): I do not have a relationship with a for-profit and/or a not-for-profit organization to disclose

Committee Member(s)

Megha Poddar, MD, FRCPC, ABOM

Clinical Director
LMC Weight Management Clinic
McMaster University
Toronto, Ontario, Canada

Disclosure information not submitted.

Moderator(s)

LR

Laura Reardon, MD

Disclosure information not submitted.

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada and approved by the Canadian Society of Endocrinology and Metabolism.
This accredited symposium was co-developed with the Canadian Society of Endocrinology and Metabolism and Novo Nordisk and was planned to achieve scientific integrity, objectivity and balance.

Learning Objectives:

Recognize interdisciplinary roles and approaches in the comprehensive care of individuals living with overweight or obesity.
Analyze the safety and efficacy profiles of obesity medications and their impact on cardiovascular risk based on recent clinical trial data.
Develop strategies to effectively communicate clinical trial outcomes and treatment benefits to patients living with obesity.